Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
ALLO Analyst Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ALLO Stock 12 Month Forecast
Average Price Target
$8.50
▲(424.69% Upside)
| Highest Price Target$14.00 | Average Price Target$8.50 | Lowest Price Target$4.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
Reiterated
03/19/25
Stifel Nicolaus
Reiterated
03/17/25
William Blair
Reiterated
03/14/25
Piper Sandler
Reiterated
03/14/25
Canaccord Genuity
Reiterated
03/14/25
Oppenheimer
Reiterated
03/14/25
Citi
Reiterated
03/14/25
JMP Securities
Upgraded
03/14/25
TD Cowen
Reiterated
03/13/25
RBC Capital
Reiterated
03/13/25
Truist Financial
―
Buy
―
Reiterated
02/18/25
Truist Financial Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)
Robert W. Baird
―
Buy
―
Reiterated
02/18/25
Baird 'encouraged' by Allogene CAR-T therapy updateBaird 'encouraged' by Allogene CAR-T therapy update
B.Riley Financial
$10→$7
Buy
332.10%
Upside
Reiterated
05/14/24
Allogene (ALLO) PT Lowered to $7 at B.RileyB.Riley analyst Kalpit Patel lowered the price target on Allogene (NASDAQ: ALLO) to $7.00 (from $10.00) while maintaining a Buy rating.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
03/19/25
Stifel Nicolaus
Reiterated
03/17/25
William Blair
Reiterated
03/14/25
Piper Sandler
Reiterated
03/14/25
Canaccord Genuity
Reiterated
03/14/25
Oppenheimer
Reiterated
03/14/25
Citi
Reiterated
03/14/25
JMP Securities
Upgraded
03/14/25
TD Cowen
Reiterated
03/13/25
RBC Capital
Reiterated
03/13/25
Truist Financial
―
Buy
―
Reiterated
02/18/25
Truist Financial Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)
Robert W. Baird
―
Buy
―
Reiterated
02/18/25
Baird 'encouraged' by Allogene CAR-T therapy updateBaird 'encouraged' by Allogene CAR-T therapy update
B.Riley Financial
$10→$7
Buy
332.10%
Upside
Reiterated
05/14/24
Allogene (ALLO) PT Lowered to $7 at B.RileyB.Riley analyst Kalpit Patel lowered the price target on Allogene (NASDAQ: ALLO) to $7.00 (from $10.00) while maintaining a Buy rating.
Best Analysts Covering Allogene Therapeutics
Which Analyst Should I Follow If I Want to Buy ALLO and Sell After:
1 Month
xxx
Success Rate
5/14 ratings generated profit
Average Return
-8.04%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 35.71% of your transactions generating a profit, with an average return of -8.04% per trade.
3 Months
xxx
Success Rate
6/14 ratings generated profit
Average Return
-3.31%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -3.31% per trade.
1 Year
Success Rate
4/21 ratings generated profit
Average Return
-26.04%
reiterated a buy rating 11 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 19.05% of your transactions generating a profit, with an average return of -26.04% per trade.
2 Years
xxx
Success Rate
1/14 ratings generated profit
Average Return
-44.40%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 7.14% of your transactions generating a profit, with an average return of -44.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ALLO Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
16
8
8
3
9
Buy
5
3
3
3
5
Hold
5
3
3
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
14
14
6
15
Each month's total comprises the sum of three months' worth of ratings.
ALLO Financial Forecast
ALLO Stock Forecast FAQ
What is ALLO’s average 12-month price target, according to analysts?
Based on analyst ratings, Allogene Therapeutics Inc’s 12-month average price target is $8.50.
What is ALLO’s upside potential, based on the analysts’ average price target?
Allogene Therapeutics Inc has 424.69% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALLO a Buy, Sell or Hold?
Allogene Therapeutics Inc has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
What is Allogene Therapeutics Inc’s price target?
The average price target for Allogene Therapeutics Inc is $8.50. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $4.00. The average price target represents 424.69% Increase from the current price of $1.62.
The highest analyst price target is $14.00 ,the lowest forecast is $4.00. The average price target represents 424.69% Increase from the current price of $1.62.
What do analysts say about Allogene Therapeutics Inc?
Allogene Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of ALLO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.